Rakic, J., Leys, A., Brié, H., Denhaerynck, K., Pacheco, C., Vancayzeele, S., . . . Abraham, I. (2013). Real-world variability in ranibizumab treatment and associated clinical, quality of life, and safety outcomes over 24 months in patients with neovascular age-related macular degeneration: The HELIOS study. Dove Medical Press.
Chicago Style citaatRakic, Jean-Marie, Anita Leys, Heidi Brié, Kris Denhaerynck, Christy Pacheco, Stefaan Vancayzeele, Christine Hermans, Karen MacDonald, en Ivo Abraham. Real-world Variability in Ranibizumab Treatment and Associated Clinical, Quality of Life, and Safety Outcomes Over 24 Months in Patients With Neovascular Age-related Macular Degeneration: The HELIOS Study. Dove Medical Press, 2013.
MLA citatieRakic, Jean-Marie, et al. Real-world Variability in Ranibizumab Treatment and Associated Clinical, Quality of Life, and Safety Outcomes Over 24 Months in Patients With Neovascular Age-related Macular Degeneration: The HELIOS Study. Dove Medical Press, 2013.